Groupe la Francaise Buys Shares of 75,932 Inhibrx Biosciences, Inc. $INBX

Key Points

• Groupe la Francaise has acquired a new position in Inhibrx Biosciences, purchasing 75,932 shares valued at approximately $1,062,000, which represents about 0.52% of the company.
• Inhibrx Biosciences reported an earnings per share (EPS) of ($1.85) for the last quarter, surpassing analysts' estimates of ($2.92) by $1.07.
• Despite recent investments from several institutional investors, Inhibrx Biosciences currently has a consensus rating of "Hold" from analysts, with Wall Street Zen upgrading it from a "sell" to a "hold" rating.

Groupe la Francaise bought a new position in Inhibrx Biosciences, Inc. (NASDAQ:INBX - Free Report) in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 75,932 shares of the company's stock, valued at approximately $1,062,000. Groupe la Francaise owned 0.52% of Inhibrx Biosciences as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently made changes to their positions in INBX. JPMorgan Chase & Co. lifted its stake in shares of Inhibrx Biosciences by 47.8% in the 4th quarter. JPMorgan Chase & Co. now owns 7,592 shares of the company's stock worth $117,000 after acquiring an additional 2,457 shares during the period. Geode Capital Management LLC acquired a new stake in shares of Inhibrx Biosciences in the 4th quarter worth $3,930,000. Wells Fargo & Company MN acquired a new stake in shares of Inhibrx Biosciences in the 4th quarter worth $102,000. Barclays PLC acquired a new stake in shares of Inhibrx Biosciences in the 4th quarter worth $289,000. Finally, Marshall Wace LLP acquired a new stake in shares of Inhibrx Biosciences in the 4th quarter worth $825,000. Institutional investors and hedge funds own 82.46% of the company's stock.

Inhibrx Biosciences Price Performance

Shares of INBX traded up $0.48 during trading hours on Thursday, reaching $27.88. The company had a trading volume of 126,178 shares, compared to its average volume of 106,782. The firm has a 50 day simple moving average of $21.24 and a 200-day simple moving average of $15.85. The company has a current ratio of 4.98, a quick ratio of 4.98 and a debt-to-equity ratio of 1.45. The company has a market capitalization of $403.70 million, a price-to-earnings ratio of -2.64 and a beta of 0.24. Inhibrx Biosciences, Inc. has a 12-month low of $10.81 and a 12-month high of $28.16.

Inhibrx Biosciences (NASDAQ:INBX - Get Free Report) last announced its quarterly earnings results on Wednesday, August 13th. The company reported ($1.85) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($2.92) by $1.07. The company had revenue of $1.30 million during the quarter. Research analysts expect that Inhibrx Biosciences, Inc. will post 104.88 earnings per share for the current year.

Analysts Set New Price Targets

Several research firms have recently commented on INBX. JMP Securities restated a "market perform" rating on shares of Inhibrx Biosciences in a research note on Friday, August 22nd. Wall Street Zen upgraded shares of Inhibrx Biosciences from a "sell" rating to a "hold" rating in a research note on Sunday, August 17th. One analyst has rated the stock with a Hold rating, According to MarketBeat, the stock currently has an average rating of "Hold".

About Inhibrx Biosciences

Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.